Spiration Valve System 9 mm European Post Market Evaluation Study

Inclusion Criteria: * Patient is older than 40 years in age * Patient has severe heterogeneous emphysema with moderate to severe dyspnea as defined as an mMRC of 2 or greater. * The target lobe and ipsilateral lobe will be separated with an intact fissure, as determined by HRCT (\> 90% integrity). * Patient has received standard-of-care medical management and it has been stable for 6 weeks. * Patient can walk a minimum of 140 meters in the six minute walk test. * Patient's obstructive disease is severe as defined by: FEV1 ≤45% of predicted * Patient's hyperinflation is defined by: RV ≥ 150% of predicted * Patient is willing to participate in a study, complete the required follow-up visits, and maintain consistent nutrition and exercise habits during the study period Exclusion Criteria: * Patient does not have at least one airway with the intention to be treated with a 9 mm Spiration Valve based on a calibrated balloon sizing of the airway. * Patient has co-existing major medical disease that will limit evaluation, participation, or follow-up in the study * Patient is unable to provide informed consent * Patient is not an appropriate candidate for or is unable to tolerate, flexible bronchoscopy procedures * Patient has history of 4 or more hospitalizations for COPD exacerbation or respiratory infections in the past year and none have occurred in the 3 months prior to baseline testing. * Patient has giant bulla (\> 1/3 volume of lung) * Patient has severe pulmonary hypertension. * Patient has bronchiectasis * Patient has evidence of systemic disease or neoplasia expected to compromise survival during the 6-month study period * Patient has had prior lung volume reduction surgery, intra-bronchial valve therapy for emphysema, or major lung procedures (lobectomy or greater). * Patient has demonstrated unwillingness or inability to complete screening or baseline data collection procedures. * Patient participated in a study of an investigational drug or device within the past 30 days prior to participation in this study, or is currently participating in another clinical study